| Page 125 | Rogel Cancer Center | University of Michigan

Connect to our Media Team Reporters and editors: For expert sources, information on our press releases, or other immediate help, call 734-764-2220 between 8 a.m. and 5 p.m. Eastern time, Monday through Friday. After business hours (from 5 to 11 p.m. and 7 to 8 a.m. ET), and from 7 a.m. to 11 p.m. on weekends and holidays, members of the media may call the Michigan Medicine operators at 734-936-6267 to page a media team member for patient condition reports or highly urgent matters. Read more about Connect to our Media Team	A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) This trial is no longer accepting participants. To get information / assistance to help you find a clinical trial that's right for you, please call 800-865-1125. Read more about A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)	SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms Information about this clinical trial has moved. You can learn about it on this page. Read more about SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms	Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor This trial is no longer accepting participants. For information / assistance to help you learn what clinical trials are right for you, please call Cancer AnswerLine at 800-865-1125. Read more about Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) This trial is no longer accepting participants. For information / assistance in finding a clinical trial that is right for you, please contact Cancer AnswerLine: 800-865-1125. Read more about Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease This trial is no longer accepting participants. For information / assistance about finding a clinical trial that's best for you, please call 800-865-1125. Read more about Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease	A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) This trial is no longer accepting participants. To get information / assistance in finding a clinical trial that's right for you, please call Cancer AnswerLine at 800-865-1125. Read more about A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)	A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer This trial is no longer accepting participants. To get assistance / information to find a clinical trial that is right for you, please call Cancer AnswerLine at 800-865-1125. Read more about A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors Information about this study has moved. You can now read about it on this page. Read more about A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors	A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies Information about this clinical trial has moved. You can now learn about it on this page. Read more about A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies

Reporters and editors: For expert sources, information on our press releases, or other immediate help, call 734-764-2220 between 8 a.m. and 5 p.m. Eastern time, Monday through Friday.

Pages